Notwithstanding the muted broader market trend, shares of Biocon Ltd surged over 3 per cent on Friday after the biotechnology major reported strong December quarter earnings. On BSE, the stock opened at Rs 363, then touched a high of Rs 382.45, registering a gain of 5.09 per cent over its last close. The stock finally ended at Rs 376.60, up 3.49 per cent. In a similar trend on NSE, the stock opened at Rs 364.00, then jumped 5.02 per cent and touched an early high of Rs 382.50 in initial deals. It finally settled at Rs 376.45, up 3.36 per cent. On Thursday, biotechnology major Biocon Ltd reported a 17.68 per cent rise in consolidated net profit at Rs 219.6 crore for the third quarter ended December 31, 2021. The company had posted a consolidated net profit of Rs 186.6 crore in the same quarter of the previous fiscal. Consolidated total income in the third quarter this fiscal stood at Rs 2,222.5 crore, compared to Rs 1,885.3 crore a year ago. The biosimilars vertical clocked revenue
Mylab MD Rawal said the firm is making both hardware and software for the test, and it will be ready in the next two months or so
The facility for genome Sequencing has been started in the SMS Medical College
The Pune-based firm, which has a presence across many verticals like diagnostics, food safety, agriculture and veterinary medicine
Her startup has so far handled 1,400 cases making 3D models of patients' body parts, assisting doctors to study the organ without opening up the patient in the operation theatre
Not all great ideas are nurtured at IITs and IIMs; many enterprises with formidable products today have come from the country's deeper regions and have received parenting at lesser known institutes
Pacific Biosciences of California Inc said on Wednesday SoftBank Group Corp will invest $900 million in the gene sequencing firm
Industrial biotechnology company Praj Industries on Friday said it has bagged a Rs 226.90 crore order from Indian Oil Corporation Ltd
Bio-economy uses renewable biological resources sustainably to produce food, energy and industrial goods.
There are speculations on whether the government's policy on genetically engineered products has undergone a subtle, even if undeclared, change. If it is so, it is welcome
Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells
The US Food and Drug Administration (FDA) will have to approve the change in the Phase 3 Covid-19 vaccine trial before it goes into effect
PARIS (Reuters) - Sanofi SA is to buy U.S.-based Principia Biopharma Inc for around $3.7 billion, the companies announced on Monday, marking the French healthcare company's latest acquisition in the biotech sector.
"India's biotechnology economy can approach $100 billion in 2025 if the right policies are put in place, giving industry the required stimulation," he said
India has the potential to develop an antidote to Covid-19
Kilpest India, one of the companies that have received ICMR's approval to produce RT-PCR kits for Covid-19 testing, has seen its share price more than double since April 1
Mankind became the first Indian and second global company to develop a dydrogesterone containing drug for treatment of pregnancy-related complications
Biocon Biologics, through its partner Mylan, has commercialised three of its co-developed biosimilars in developed markets like the US, Canada, the European Union and Australia.
Of the 3,000 entrepreneurs who've started biotech firms in the past 5 years, a third are women
Draft policy provides land on priority for projects, 33% subsidy on plant & machinery; power cost reimbursed at a rupee per unit